“--where are the hedgefunds buying 10 percent of such a high yielding company..”
You have to give guidance to accredited analyst that advise fund managers. Zero guidance means zero analysts. No open Q&A means zero analyst and that leads to zero large fund managers taking an interest. Last ASM had zero financial condition information like what we have spent on Eden and how much more we will spend? What was the present cash position and how much more needed until approaching approval?
Money managers do not want to lose money and analysts do not want to give them bad information.
Any biopharma out there could buy 75 million shares as a guaranteed investment with a 5000% ROI , even if they had no ability to buy the company . It doesn’t make sense for any entity with an extra $35 million , to not invest in NWBO /DCVax at this point, just as a solid investment of cash.
Woodford was a fund(s) manager and she ignored him and any reasonable direction he wanted to see while he was funding things. Now Woodford had his own demise but if we partnered with a large pharmaceutical we would not be where we are today.
After Woodford I imagine any fund managers approach with caution. Bigger was just smart because he saw distressed assets. With warrants I am sure he has already gotten his money back 5 fold.
News 
Market Data 
Discover 
